Ligand Boosts Royalty Portfolio with XOMA Acquisition and Strong Q2 Growth — Ligand Pharmaceuticals Incorporated

Event summary

Ligand reported a 32% year-over-year increase in royalty revenue for Q2 2026, driven by strong performance from Filspari, Zelsuvmi, and Ohtuvayre.
The company completed the acquisition of XOMA Royalty, adding over 120 commercial, clinical, and preclinical-stage assets to its portfolio.
Ligand raised the low end of its 2026 adjusted EPS guidance to $9.00–$9.50 from $8.50–$9.50, citing stronger cost synergies and incremental net interest income.
Total revenues for Q2 2026 were $63.7 million, up 34% year-over-year, with royalties totaling $48.0 million.

The big picture

Ligand's strategic focus on royalty aggregation is reinforced by the XOMA acquisition, positioning it as a leading player in the biopharma royalty space. The company's strong Q2 performance and raised EPS guidance reflect its ability to capitalize on growing demand for rare disease treatments and innovative therapeutics. With over 200 assets in its portfolio, Ligand is well-positioned to benefit from the increasing trend of outsourcing drug development financing to specialized aggregators.

What we're watching

Integration Success: How Ligand will integrate XOMA Royalty's assets and whether the acquisition will meet its projected earnings contributions.
Royalty Revenue Growth: The pace at which Ligand can sustain royalty revenue growth from key products like Filspari, Ohtuvayre, and Zelsuvmi.
Capital Deployment Strategy: Whether Ligand's $700 million in deployable capital will be effectively used for additional high-value royalty acquisitions.